Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants

A. Dias, M. Brook, E. Bancroft, E. Page, A. Chamberlain, S. Saya,Jan Amin, C. Mikropoulos, N. Taylor, K. Myhill,Sarah Thomas, E. Saunders,Tokhir Dadaev, D. Leongamornlert,Thomas Dyrsø Jensen, D. G. Evans, C. Cybulski, A. Liljegren, Soo-Hwang Teo, L. Side, Z. Kote-Jarai, R. Eeles

BJUI Compass（2023）

Cited 0|Views2

No score

Abstract

The relation of serum androgens and the development of prostate cancer (PCa) is subject of debate. Lower total testosterone (TT) levels have been associated with increased PCa detection and worse pathological features after treatment. However, data from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) and Prostate Cancer Prevention (PCPT) trial groups indicate no association. The aim of this study is to investigate the association of serum androgen levels and PCa detection in a prospective screening study of men at higher genetic risk of aggressive PCa due to BRCA1/2 pathogenic variants (PVs), the IMPACT study.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined